drugset / Trial / NCT04134468
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of locally advanced pancreatic cancer patient tumors. Subjects will received Gemcitabine, Abraxane and PEGPH20.
Timeline
- Start
- 2020-01
- Primary completion
- 2021-02-11
- Completion
- 2022-11-11
Outcome
Outcome not reported
Stopped: “Halozyme halted development of PEGPH20 following Phase 3 failure.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEGPH20 | Protein / enzyme biologic | 3 ug/kg | Intravenous |
| Background | Abraxane | Small molecule | 125 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |